488 OriA631-B: a first-in class CD39/PD-L1 bispecific antibody unleashing enhanced cancer immunotherapy - Yuchen Zhang; Huajing Wang; Xian-Yang Li; Xiaowen He; Xiaopei Li; Qi Deng (Journal for ImmunoTherapy of Cancer, 2023)